|本期目录/Table of Contents|

[1]王 雨,陈 鑫,叶 梅,等.云南省红河州和德宏州吸毒人群中HIV-1/HCV 共感染者HIV-1 耐药性分析[J].传染病信息,2018,04:356-359.
 WANG Yu,CHEN Xin,YE Mei,et al.HIV-1 drug resistance among HIV-1/HCV co-infected drug users in Honghe and Dehong Prefectures of Yunnan Province[J].Infectious Disease Information,2018,04:356-359.
点击复制

云南省红河州和德宏州吸毒人群中HIV-1/HCV 共感染者HIV-1 耐药性分析(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2018年04期
页码:
356-359
栏目:
论 著
出版日期:
2018-08-30

文章信息/Info

Title:
HIV-1 drug resistance among HIV-1/HCV co-infected drug users in Honghe and Dehong Prefectures of Yunnan Province
作者:
王 雨陈 鑫叶 梅熊思东郑永唐
215000,苏州大学药学院(王雨);650223,中 国科学院昆明动物研究所(陈鑫、叶梅、郑永唐);215000, 苏州大学- 中国科学院昆明动物研究所疾病动物模型与新药研 发联合实验室(王雨、熊思东、郑永唐)
Author(s):
WANG Yu CHEN Xin YE Mei XIONG Si-dong ZHENG Yong-tang*
College of Pharmaceutical Sciences, Soochow University, 215000, China KIZ-SU Joint Iaboratory of Animal Model and Drug Development, College of Pharmaceutical Sciences, Soochow University, 215000, China
关键词:
HIV-1/HCV 共感染耐药性吸毒人群
Keywords:
HIV-1/HCV co-infection drug resistance drug users
分类号:
R512.91 
DOI:
10.3969/j.issn.1007-8134.2018.04.014
文献标识码:
A
摘要:
目的 了解云南省红河州和德宏州吸毒人群中HIV-1/HCV 共感染者HIV-1 耐药情况,为该地区该人群的 抗病毒治疗提供理论指导。方法 筛查HIV-1/HCV 共感染吸毒患者血液样本,对HIV-1 pol 基因耐药位点进行测序及 比对分析。结果 在305 例HIV-1/HCV 共感染吸毒者中,成功获得pol 基因的有202 例。其中有32 例接受HIV-1 抗病 毒治疗,81 例未接受治疗,89 例治疗信息未知。治疗组的耐药发生率为40.6%(13/32),显著高于未治疗组的8.6% (7/81)(P < 0.05)。治疗组主要对奈韦拉平、依非韦伦、拉米夫定、司他夫定和恩曲他滨高度耐药,而未治疗组 仅个别对沙奎那韦、依曲韦林和利匹韦林高度耐药。结论 云南省红河州和德宏州吸毒人群中HIV-1/HCV 共感染者 HIV-1 耐药发生率处于较高水平,且现有的一线、二线治疗方案仍行之有效,一线治疗失败者应尽早转入二线治疗。 
Abstract:
Objective To investigate the HIV-1 drug resistance among HIV-1/HCV co-infected drug users in Honghe and Dehong Prefectures of Yunnan Province and provide theoretical preference of HIV-1 antiretroviral therapy for HIV-1/HCV co-infected drug users in the areas. Methods Blood samples of HIV-1/HCV co-infected cases were collected through a survey. HIV-1 pol fragment was used for drug resistance mutation sequencing and analysis. Results From 305 HIV-1/HCV coinfected drug users, 202 HIV-1 pol fragments were successfully amplified and analyzed. Among them, 32 cases received HIV-1 antiretroviral treatment, 81 cases did not, the rest 89 cases was unknown. The rate of drug resistance in treated group (40.6%, 13/32) was significantly higher than that in untreated group (8.6%, 7/81) (P < 0.05). Most treated cases exhibited high-level resistance to Nevirapine, Efavirenz, Lamivudine, Stavudine and Emtricitabine; While, only a few untreated cases conferred high resistance to Saquinavir, Etravirine and Rilpivirine. Conclusions The prevalence of HIV-1 drug resistance among HIV-1/HCV co-infected drug users in Honghe and Dehong Prefectures of Yunnan Province is relatively high, and the current first-line and second-line treatments are still effective. Those who failed in first-line treatment are strongly advised to be given second-line treatment as early as possible.   

参考文献/References


[1] 叶梅,陈鑫,王雨,等. HIV-1 阳性配偶/ 固定性伴的分子流 行病学研究进展[J]. 传染病信息,2016,29(6):358-363.
[2] Arenas M. Genetic consequences of antiviral therapy on HIV-1[J]. Comput Math Methods Med, 2015, 2015(2):1-9.
[3] 陈敏,王继宝,邢辉,等. 云南省德宏傣族景颇族自治州 2015 年HIV-1 耐药传播警戒线调查[J]. 中华流行病学杂志, 2017,38(7):959-962.
[4] 杨翠先. 中国云南省HIV/AIDS 患者基因变异与耐药的研究 [D]. 重庆:第三军医大学,2015.
[5] 姚仕堂,姚媛, 时允,等. 云南省德宏州2012-2014 年成年 艾滋病患者抗病毒治疗耐药发生及影响因素研究[J]. 中华 流行病学杂志,2016,37(7):949-954.
[6] Yang C, Yang S, Li J, et al. Genetic diversity and drug resistance among antiretroviral treatment-failed individuals from 2010 to 2012 in Honghe, China[J]. AIDS Res Hum Retroviruses, 2015, 31(8):822-829.
[7] Zhou YH, Liang YB, Pang W, et al. Diverse forms of HIV among Burmese long-distance truck drivers imply their contribution to HIV-1 cross-border transmission[J]. BMC Infect Dis, 2014, 26(14):463.
[8] Zhou YH, Yao ZH, Liu FL, et al. High prevalence of HIV, HCV, HBV and co-infection and associated risk factors among injecting drug users in Yunnan Province, China[J]. PLoS One, 2012, 7(8):e42937.
[9] Chen M, Ma Y, Duan S, et al. Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naive HIV-infected individuals in western Yunnan: a hot area of viral recombination in China[J]. BMC Infect Dis, 2012, 12(1):382.
[10] Li H, Zhong M, Guo W, et al. Prevalence and mutation patterns of HIV drug resistance from 2010 to 2011 among ART-failure individuals in the Yunnan Province, China[J]. PLoS One, 2012, 8(8):e72630.
[11] 吴欣华,杨兰辉,霍松,等. 红河州HAART 的HIV/AIDS 病 人的耐药性及其影响因素[J]. 中国艾滋病性病,2014, 20(10):730-733.
[12] 李重熙, 白劲松, 刘俊, 等. 昆明地区HIV 感染高效抗 病毒治疗后基因型耐药分析[J]. 皮肤病与性病,2014, 36(3):137-139.
[13] Rocheleau G, Franco-Villalobos C, Oliveira N, et al. Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada [J]. PLoS One, 2017, 12(9):e0184848.
[14] 杨绍敏,钟敏,杨壁珲,等. 云南省2008—2012 年HIV-1 耐 药基因型检测情况[J]. 中国艾滋病性病,2014,20(1):9-12.
[15] 杨翕然,杨翠先,杨绍敏,等. 临沧市2012 年高效抗反转录 病毒治疗失败的AIDS 患者耐药基因变异分析[J]. 传染病信 息,2014,27(3):164-166.
[16] Chen Y, Chen S, Kang J, et al. Evolving molecular epidemiological profile of human immunodeficiency virus 1 in the southwest border of China[J]. PLoS One, 2014, 9(9):e107578.
[17] Wittayanarakul K, Aruksakunwong O, Saen-oon S, et al. Insights into saquinavir resistance in the G48V HIV-1 protease: quantum calculations and molecular dynamic simulations[J]. Biophys J, 2005, 88(2):867-879.

备注/Memo

备注/Memo:
[ 基金项目] 国家自然科学基金面上项目(81271892, 81601802); 国家自然科学基金委员会- 云南联合基金 (U1302224) [ 作者单位] 215000,苏州大学药学院(王雨);650223,中 国科学院昆明动物研究所(陈鑫、叶梅、郑永唐);215000, 苏州大学- 中国科学院昆明动物研究所疾病动物模型与新药研 发联合实验室(王雨、熊思东、郑永唐) [ 通信作者] 郑永唐,E-mail: zhengyt@mail.kiz.ac.cn
更新日期/Last Update: 2018-09-08